Overall, we provide insights supporting tailored strategies to overcome HER2 expression-associated immunodepletion, including combinations of immunotherapy with ADCs or agents targeting B-cell/TLS axes, aiming to expand options in HER2-negative breast cancer patients. The gene discussed is ERBB2; the disease is breast cancer.